This paper is only available as a PDF. To read, Please Download here.
Background. Cytotoxic T lymphocytes (CTL) have been shown to be useful for adoptive immunotherapy in malignancy. Traditional sources for CTL, such as tumor-infiltrating lymphocytes, have limitations. It would therefore be useful to develop a method of generating antitumor CTL from a renewable source such as peripheral blood.
Methods. DBA/2 mice were injected intradermally in the abdominal wall with the murine tumor PHS-5 and killed 14 days later. Peripheral blood lymphocytes were harvested and cultured with 20 units/ml interleukin-2 and autologous tumor-stimulator cells treated with mitomycin C. Cultures were split when greater than 2 × 106 cells/well, fed every 3 days and stimulated weekly.
Results. Lymphocytes expanded greater than 130,000-fold during 8 weeks. Specific cytotoxicity was shown with 51Cr release assay. Withdrawal of repeated stimulation with autologous tumor resulted in failure of cells to expand in culture and loss of cytotoxicity. In vivo administration showed marked reduction of 10-day liver metastases, indicating therapeutic efficacy.
Conclusions. These data demonstrate a successful animal model of adoptive immunotherapy with CTL generated from peripheral blood lymphocytes.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Surgery
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.Science. 1986; 233: 1318-1321
- Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma.N Engl J Med. 1988; 319: 1676-1680
- Tumor-specific cytolysis by lymphocytes infiltrating human melanomas.J Immunol. 1989; 142: 3714-3725
- Characterization of cells from invaded lymph nodes in patients with solid tumors: lymphokine requirement for tumor-specific lymphoproliferative response.J Exp Med. 1987; 166: 303-318
- Human cytotoxic T cells specific for autologous melanoma cells: successful generation from lymph node cells in seven consecutive cases.J Natl Cancer Inst. 1988; 80: 1016-1026
- Melanoma-specific cytotoxic T cells generated from peripheral blood lymphocytes: implications of a renewable source of precursors for adoptive cellular immunotherapy.Ann Surg. 1989; 210: 193-201
- Comparative studies of the long-term growth of lymphocytes from tumor infiltrates, tumor-draining lymph nodes and peripheral blood by repeated in vitro stimulation with autologous tumor.J Biol Response Mod. 1990; 9: 431-438
- Activation and expansion of cytotoxic T lymphocytes from tumor-draining lymph nodes.Cancer Immunol Immunother. 1990; 32: 38-44
- Production of tumor-specific suppressor T-cell hybridomas.J Surg Res. 1987; 42: 369-376
- Tumor-specific suppressor T-cells which inhibit the in vitro generation of cytolytic T-cells from immune and early tumor-bearing host spleens.Cancer Res. 1986; 46: 1805-1812
- Accurate identification of experimental pulmonary metastases.J Natl Cancer Inst. 1966; 36: 641-645
- What's new in general surgery: the development of new immunotherapies for the treatment of cancer using interleukin-2.Ann Surg. 1987; 208: 121-134
- Solid-phase anti-CD 3 antibody activation of murine tumor-infiltrating lymphocytes.Cancer Res. 1990; 50: 2587-2592
- Calcium ionophore plus phorbol ester can substitute for antigen in the induction of cytolytic T lymphocytes from specifically primed precursors.J Immunol. 1985; 135: 2262-2267
- MHC-restricted recognition of autologous melanoma by tumorspecific cytotoxic T cells: evidence for restriction by a dominant HLA-A allele.J Immunol. 1991; 146: 1692-1699
- Activation and in vitro expansion of tumor-reactive T-lymphocytes from lymph nodes draining human primary breast cancers.J Surg Oncol. 1991; 46: 117-124
Accepted: February 1, 1992
☆Supported by the Alberta Cancer Board.
© 1993 Published by Elsevier Inc.